ERBB2 and breast carcinoma: Downregulation of Her2 recently resulted highly effective in promoting cell death in breast cancer models, exhibiting a synergistic effect with taxane [94]; however, Her2 reduction leads to the production of cytokines that might promote tumor recurrence [95].